AUVIZRI
Live / Registered — Registered (as of 23 Apr 2024)
What this means for you
Registered since 23 Apr 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97782421
- Registration number
- 7363834
- Mark type
- Stylized text
- Filed
- 06 Feb 2023
- Published for opposition
- 19 Dec 2023
- Registered
- 23 Apr 2024
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, and immune system related diseases and disorders; all of the foregoing excluding pharmaceutical preparations for the treatment of psychiatric related diseases and disorders, including depression
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 23 Apr 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 Apr 2024 — REGISTERED-PRINCIPAL REGISTER
- 15 Mar 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 13 Mar 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 05 Mar 2024 — POST PUBLICATION AMENDMENT - ENTERED
- 04 Mar 2024 — ASSIGNED TO PETITION STAFF
- 02 Feb 2024 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 05 Jan 2024 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 19 Dec 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Dec 2023 — PUBLISHED FOR OPPOSITION
- 29 Nov 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Nov 2023 — ELECTRONIC RECORD REVIEW COMPLETE
- 10 Nov 2023 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 03 Nov 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Oct 2023 — ASSIGNED TO EXAMINER